Argenx Stock Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans
· investors.com
Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
10/08/2026 Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjog...